Molecular Partners (MOLN) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Molecular Partners (MOLN) has outperformed Zura Bio (ZURA) over the past year, losing 37.5% versus a loss of 74.4%. Molecular Partners is the larger company by market cap ($96.8 million vs $89.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MOLN | ZURA |
|---|---|---|
| Share price | $2.53 | $0.9305 |
| Market cap | $96.80M | $89.63M |
| 1-day change | -5.25% | -2.30% |
| YTD return | -42.07% | -82.24% |
| 1-year return | -37.50% | -74.37% |
| 5-year return | -77.87% | — |
| EPS (TTM) | $-1.68 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-68.65M |
| 52-week high | $5.36 | $7.44 |
| 52-week low | $2.52 | $0.919 |
| Distance from 52-week high | -52.89% | -87.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +295.64% | +759.75% |
| Average volume | 1.63K | 4.47M |
| Shares outstanding | 38.34M | 96.33M |
| Employees | 134 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed ZURA by 36.9 percentage points over the past year.
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
MOLN vs ZURA FAQ
Which is bigger, Molecular Partners or Zura Bio?
Molecular Partners (MOLN) is larger, with a market capitalization of $96.80M compared with $89.63M for Zura Bio (ZURA).
Which stock has performed better over the past year, MOLN or ZURA?
MOLN returned -37.50% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.
Are Molecular Partners and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.